Loading...

CFSE Cell Division Tracker Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
5-(and 6)-Carboxyfluorescein diacetate succinimidyl ester Kit, CFDA SE Kit
Ave. Rating
Submit a Review
Product Citations
publications
CFSE_Cell_Tracking_Kit_022014
Human peripheral blood mononuclear cells were stained with CFSE Cell Division Tracking Kit, and then stimulated with (filled histogram) or without (open histogram) PHA for 5 days. On day 5, cells were harvested and the CFSE fluorescent staining was analyzed by flow cytometry.
  • CFSE_Cell_Tracking_Kit_022014
    Human peripheral blood mononuclear cells were stained with CFSE Cell Division Tracking Kit, and then stimulated with (filled histogram) or without (open histogram) PHA for 5 days. On day 5, cells were harvested and the CFSE fluorescent staining was analyzed by flow cytometry.
Cat # Size Price Quantity Check Availability Save
423801 1 kit 81€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CFSE Cell Division Tracker Kit is composed of 5 vials, 100 µg per vial of CFSE (formally known as 5-(and 6)-Carboxyfluorescein diacetate succinimidyl ester of CFDA SE), and 500 µl of anhydrous DMSO. CFSE is able to passively diffuse into cells. Inside the cell, its acetate groups are cleaved by intracellular esterases, and the molecules are converted to fluorescent esters. CFSE is retained within the cell and covalently couples to intracellular molecules via its succinimidyl group. Due to this covalent coupling reaction, fluorescent CFSE can be retained within the cell for an extremely long period. Also, due to this stable linkage, once the dye has been incorporated within the cell, it is not transferred to adjacent cells. CFSE is widely used for cell proliferation assays and in vivo cell tracking.

Product Details
Technical Data Sheet (pdf)

Product Details

Preparation
The CFSE Cell Division Tracker Kit is composed of lyophilized CFSE and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 36 µl of DMSO to one vial of CFSE dye until fully dissolved.
Storage & Handling
Store CFSE Cell Division Tracker Kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the CFSE, use immediately, or store at -20°C in a dry place and protected from light, preferably in a dessicator or in a container with desiccant for no more than one month.
Application

ICFC - Quality tested
In vivo cell tracking1 - Reported in the literature, not verified in house
Recommended Usage

This lot has been tested by flow cytometric analysis of in vitro cell proliferation assay. It can be used at concentrations ranging from 0.5 - 10 µM for cell labeling. It is recommended that the reagent be titrated for optimal performance for each cell type, culturing condition, or application.

Application Notes

The molecular weight of CFSE is 557.47. The excitation and emission wavelengths of CFSE-labeled cells are 492 nm and 517 nm, respectively. Each 100 µg vial of CFSE may be reconstituted with 36 µl of anhydrous DMSO to yield a stock concentration of 5 mM.

Materials Provided:
5 vials x 100 µg CFSE
500 µl anhydrous DMSO

CFSE Labeling Procedure: 
1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrofuge to ensure the reagent is at the bottom of the vial.
2. Prepare stock solution by reconstituting 1 vial of lyophilized CFSE dye in 36 µL of DMSO to make a 5 mM solution.
3. Prepare a 5 µM working solution by diluting 1 µL of 5 mM CFSE stock solution in 1 mL PBS for every 1 mL of cell suspension (or at an optimal working concentration as determined by titration).
4. Spin down and resuspend cells at 10-100 x 106 cells/mL in the CFSE working solution.
5. Incubate cells for 20 minutes at room temperature or 37°C and keep protected from light.
6. Quench the staining by adding 5 times the original staining volume of cell culture medium containing 10% FBS.
7. Pellet cells and resuspend in pre-warmed cell culture medium. 
8. Incubate cells for 10 minutes.
9. After incubation, CFSE labeled cells are ready for downstream applications or analysis.

Additional Product Notes

View more applications data for this product in our Scientific Poster Library.


Watch a Scientific Poster video of this product.

Application References

(PubMed link indicates BioLegend citation)
  1. Parish CR, et al. 2009. Curr. Protoc. Immunol. Unit4.9.
  2. Miller MJ, et al. 2002. Science 296:1869.
  3. Tai LH, 2013. Clin Cancer Res. 19:5104. PubMed
  4. Svajger U, et al. 2014. J Lukoc Biol. 95:33. PubMed
Product Citations
  1. Tocheva AS, et al. 2020. Curr Protoc Immunol. 130:e103. PubMed
  2. Nalbandian M, et al. 2022. Life Sci Alliance. 5: . PubMed
  3. Zhang Y, et al. 2022. Nat Med. 28:1421. PubMed
  4. Hsieh T, et al. 2022. Front Immunol. 13:901030. PubMed
  5. Liang Y, et al. 2022. Theranostics. 12:7729. PubMed
  6. Tang M, et al. 2022. Biomolecules. 12: . PubMed
  7. Zhang Z, et al. 2023. J Transl Med. 21:23. PubMed
  8. Vondra S, et al. 2023. Cell Rep. 42:111977. PubMed
  9. Garcia-Becerra N, et al. 2023. Cancers (Basel). 15: . PubMed
  10. Lin CP, et al. 2023. EMBO J. 42:e111614. PubMed
  11. Wang R, et al. 2023. iScience. 26:105954. PubMed
  12. Ma Y, et al. 2022. Am J Physiol Heart Circ Physiol. 322:H622. PubMed
  13. Sheng YR, et al. 2022. Cell Mol Life Sci. 79:173. PubMed
  14. Li Y, et al. 2022. Transl Oncol. 21:101424. PubMed
  15. Mews EA, et al. 2022. ACS Nano. 16:12185. PubMed
  16. Shen M, et al. 2022. Adv Sci (Weinh). 9:e2203523. PubMed
  17. Li L, et al. 2022. Cancer Immunol Res. 10:1475. PubMed
  18. Nasiri F, et al. 2023. Front Immunol. 14:1063838. PubMed
  19. Do-Thi VA, et al. 2023. Cancer Res Commun. 3:80. PubMed
  20. Bayat H, et al. 2023. Mol Ther Nucleic Acids. 32:432. PubMed
  21. Wu C, et al. 2023. Cancer Metab. 11:7. PubMed
  22. Romo ML, et al. 2023. PLoS Negl Trop Dis. 17:e0011386. PubMed
  23. Wang Z, et al. 2023. Mediators Inflamm. 2023:9810733. PubMed
  24. Labadie KP, et al. 2023. Cancer Gene Ther. . PubMed
  25. Ennis S, et al. 2023. iScience. 26:106943. PubMed
  26. Boland LK, et al. 2019. Front Immunol. 10:1080. PubMed
  27. Zhang R, et al. 2021. Cell Mol Immunol. 18:1222. PubMed
  28. Page N, et al. 2018. Immunity. 48:937. PubMed
  29. Zupancic E, et al. 2017. Journal of Controlled Release. 10.1016/j.jconrel.2017.05.014. PubMed
  30. Boyt DT, et al. 2020. J R Soc Interface. 17:20190815. PubMed
  31. Wen Y, et al. 2020. J Invest Dermatol. . PubMed
  32. Hickey A, et al. 2021. Front Microbiol. 12:653587. PubMed
  33. Pires D, et al. 2021. Front Immunol. 12:742822. PubMed
  34. Sawada J, et al. 2021. Am J Pathol. 191:396. PubMed
  35. Hui CW, et al. 2022. Front Immunol. 13:919854. PubMed
  36. Nguyen DT, et al. 2022. Cells. 11:. PubMed
  37. Yuan X, et al. 2022. J Extracell Vesicles. 11:e12235. PubMed
  38. Rennier K, et al. 2020. Clin Cancer Res. 26:5019. PubMed
  39. Just S, et al. 2016. Sci Rep. 6:39796. PubMed
  40. Chen X, et al. 2021. Cell Death Differ. 28:1237. PubMed
  41. Chen M, et al. 2021. Cancers (Basel). 13:. PubMed
  42. Ma C, et al. 2021. Signal Transduct Target Ther. 6:353. PubMed
  43. Saito S, et al. 2020. Nutrients. 12:. PubMed
  44. Deng H, et al. 2021. J Asthma Allergy. 14:839. PubMed
  45. Onodera T, et al. 2015. Sci Rep. 5:16801. PubMed
  46. Jones N, et al. 2021. Nat Commun. 12:1209. PubMed
  47. Guo HZ, et al. 2021. Sci Adv. 7:eabg4167. PubMed
  48. Potluri HK, et al. 2022. J Immunother Cancer. 10:. PubMed
  49. Coray M, et al. 2022. Int J Mol Sci. 23:. PubMed
  50. Moser B, et al. 2021. Mol Cancer. 20:16. PubMed
  51. Zhao J, et al. 2021. Front Immunol. 12:658420. PubMed
  52. Hawila E, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.10.104. PubMed
  53. Wang Y, et al. 2021. Sci Rep. 1.429861111. PubMed
  54. Sertori R, et al. 2022. Front Immunol. 13:928252. PubMed
  55. Zhou L, et al. 2020. Clin Cancer Res. 26:290. PubMed
  56. Lv M, et al. 2020. Cell Res. 30:966. PubMed
  57. Codo AC, et al. 2020. Cell Metab. 32:437. PubMed
  58. Lerrer S, et al. 2021. iScience. 24:103020. PubMed
  59. Di Buduo CA, et al. 2021. eLife. 10:00. PubMed
  60. Lu Z, et al. 2022. Nat Commun. 13:6623. PubMed
  61. Stinson WA, et al. 2022. JCI Insight. 7:. PubMed
  62. Yang Q, et al. 2020. Theranostics. 6.2375. PubMed
  63. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  64. Monteran L, et al. 2022. Nat Commun. 13:5797. PubMed
  65. Stirling ER, et al. 2022. J Immunother Cancer. 10:. PubMed
  66. Krueger CC, et al. 2019. Front Immunol. 10:1831. PubMed
  67. Wei C, et al. 2016. Cell Death Dis. 7:e2489. PubMed
  68. Shifrut E et al. 2018. Cell. 175(7):1958-1971 . PubMed
  69. Luo Q, et al. 2020. Cancer Sci. 111:4000. PubMed
  70. Tian M, et al. 2021. Elife. 10:. PubMed
  71. Kanemaru H, et al. 2021. iScience. 24:103067. PubMed
  72. Rodriguez RM, et al. 2019. Cell Rep. 29:860. PubMed
  73. Fassler M, et al. 2021. J Neuroinflammation. 18:19. PubMed
  74. Beghelli D, et al. 2017. Oxid Med Cell Longev. 10.1155/2017/7468064. PubMed
  75. Mercer F, et al. 2016. PLoS Negl Trop Dis. 10: 0004913. PubMed
  76. Clement CC, et al. 2021. Immunity. 54:721. PubMed
  77. Feng Y, et al. 2022. Life (Basel). 12:. PubMed
  78. Kwiecinski JM, et al. 2021. Cell Rep. 36:109462. PubMed
  79. Ho JY, et al. 2021. Mol Ther Methods Clin Dev. 21:237. PubMed
  80. Burand AJ, et al. 2020. Front Immunol. 11:143. PubMed
  81. Nenasheva T, et al. 2017. PLoS One. 12(6):e0178983. PubMed
  82. Xie X, et al. 2021. Front Immunol. 12:625808. PubMed
  83. Brockman QR, et al. 2022. JCI Insight. :. PubMed
  84. Lee SH, et al. 2022. Nat Commun. 13:5461. PubMed
  85. Kwee BJ, et al. 2019. Sci Adv. 5:eaav6313. PubMed
  86. Wettersten HI, et al. 2019. Cancer Res. 79:5048. PubMed
  87. Chang T, et al. 2020. Aging (Albany NY). 12:21147. PubMed
  88. Pires D, et al. 2021. Front Immunol. 12:647728. PubMed
  89. Lim J, et al. 2020. Sci Adv. 6:eaba1334. PubMed
  90. Chen W, et al. 2019. Arterioscler Thromb Vasc Biol. 39:2028. PubMed
  91. Montel‐Hagen A et al. 2019. Cell stem cell. 24(3):376-389 . PubMed
  92. Sung J, et al. 2015. J Infect Dis. 212: 258 - 263. PubMed
  93. Zheng Z, et al. 2021. Biomed Res Int. 2021:5535578. PubMed
  94. Konda P, et al. 2022. Am J Cancer Res. 12:210. PubMed
  95. Soloff A, et al. 2017. J Appl Toxicol. 10.1002/jat.3465. PubMed
  96. Sen S, et al. 2018. J Immunol. 201:440. PubMed
  97. Rossnagl S, et al. 2016. PLoS Biol. 14: 1002562. PubMed
  98. Georgouli M et al. 2019. Cell. 176(4):757-774 . PubMed
  99. Ward D, et al. 2016. Haematologica. 101: 286 - 296. PubMed
  100. Lhuillier C, et al. 2021. J Clin Invest. 131:. PubMed
  101. Zhang Z, et al. 2021. Front Immunol. 12:699478. PubMed
  102. Kwantwi LB, et al. 2021. Bioengineered. 12:6996. PubMed
  103. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  104. Barsheshet Y, et al. 2017. Proc Natl Acad Sci U S A. 114:6086. PubMed
  105. Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed
  106. Bonaccorsi-Riani E, et al. 2015. PLoS One. 10: 0136106. PubMed
  107. Cao M, et al. 2021. Int J Cancer. 149:460. PubMed
  108. Ershaid N, et al. 2019. Nat Commun. 10:4375. PubMed

Antigen Details

Biology Area
Cell Biology, Cell Proliferation and Viability, Neuroscience
Antigen References

1. Parish CR, et al. 2009. Curr. Protoc. Immunol. Unit4.9.
2. Lyons AB, 2000. J. Immunol. Methods 243:147.

Gene ID
NA

Related FAQs

Can I use common compensation control for GFP, CFSE and FITC because they emit in the same channel?
It is not recommended even if they emit in the same channel because these are still different fluors with different brightness intensities. Individual compensation controls should be employed.
Go To Top Version: 5    Revision Date: 05.20.2020

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account